RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients

计划入组 1 人 · 首次发布于 2022 年 5 月 23 日

OrACELL™ vs. Connective Tissue in Miller Class 3 Defects

计划入组 24 人 · 首次发布于 2017 年 7 月 24 日

Goals for Reaching Optimal Wellness: GROWell

计划入组 480 人 · 首次发布于 2020 年 6 月 26 日

GC-007F

Claudin18.2-Targeted CAR-T Cell(Gracell Bioscience)

Anti-IL2/15Rβγc CAR-T (Gracell Biotechnologies (Shanghai) )

Graxcell Pharmaceutical, LLC

United States

BRIACELL THERAPEUTICS CORPORATION

United States

Crucell Holland B.V.

Netherlands

Key Trends from JP Morgan 2024: M&A Revival, AI Integration, and ADC Renaissance in Pharma

Claudin 18.2 Targeted Therapy Market Set to Exceed $800 Million by 2030 as Pipeline Expands Beyond Gastric Cancer

Vivo Capital Secures $740 Million for Third Cycle of Healthcare Investment Fund